---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-042659"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:27:58.011104+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Erasca reports FY2024 net loss $161.7M; cash $440.5M; pipeline on track for 2025 IND filings

## Summary
- Net loss for FY2024 $161.7M ($0.69/sh) vs $125.0M ($0.83/sh) in 2023.
- Cash, equivalents & marketable securities $440.5M at Dec 31, 2024, up from $322.0M; runway extended to H2 2027.
- R&D expenses $115.4M (excl. $22.5M in-process R&D) vs $103.8M; G&A $41.7M vs $37.7M.
- IND filings expected mid-Q2 2025 for pan-RAS glue ERAS-0015 and Q2 2025 for pan-KRAS inhibitor ERAS-4001.
- Phase 3 SEACRAFT-2 (naporafenib+trametinib) Stage 1 random data H2 2025; FDA FTD in NRASm melanoma.

## SEC filing metadata
- accession: 0000950170-25-042659
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017025042659/0000950170-25-042659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017025042659/eras-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-042659
- JSON: https://secwatch.observer/filing/0000950170-25-042659.json
- Plain text: https://secwatch.observer/filing/0000950170-25-042659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.